Recalls of acne treatments have pushed doctors and regulators to rethink safety rules, leading to stricter testing and shifts toward safer options in treatment guidelines.
Benzoyl peroxide, a common ingredient in over-the-counter acne creams and cleansers, faced major scrutiny in 2025 when the FDA found benzene, a cancer-linked chemical, in several products. The agency tested 95 acne treatments and detected elevated benzene levels in six, including La Roche-Posay Effaclar Duo, Walgreens Acne Control Cleanser, Proactiv creams, SLMD lotion, and others.[2] L’Oreal recalled all lots of Effaclar Duo in March due to these concerns, while companies like Zapzyt pulled products voluntarily after their own tests.[1][4] Benzene forms under certain conditions in benzoyl peroxide formulas, raising long-term health risks like leukemia from repeated use, though most tested products showed low or no levels.[2]
These events prompted quick regulatory action. The FDA shared plans for more testing results and urged companies to check batches still on shelves.[1][6] Manufacturers responded by adding benzene tests to quality checks, reviewing suppliers, and exploring formula tweaks to cut risks.[6] Private Label Skin Care, for example, recalled adulterated batches after FDA warnings and promised better oversight.[6]
In response, acne guidelines started emphasizing safety first. Dermatologists now stress discussing recall risks with patients and switching to alternatives when needed. This ties into broader 2025 trends toward non-antibiotic options like denifanstat, an oral drug targeting oil and inflammation, and mRNA tech for precise care.[1] Expert talks on isotretinoin, a strong acne pill, focused on clear rules for use, dosing, monitoring, and relapse prevention to avoid safety gaps seen in topicals.[3] Studies using group consensus methods aim to standardize when to use it based on acne severity, scarring risk, and mental health effects.[3]
Patients still turn to dermatologists over social media for advice, making clinician updates key during recalls.[1] Texture issues led to recalls of prescription acne and rosacea creams too, like Glenmark’s product, highlighting quality control needs across treatments.[5] Overall, these recalls speed up moves to targeted therapies, better testing, and patient-focused plans that balance effectiveness with proven safety.
Sources
https://www.dermatologytimes.com/view/dermatology-times-2025-year-in-review-acne
https://www.aol.com/popular-acne-products-recalled-due-153929010.html
https://clinicaltrials.gov/study/NCT07296523
http://dermatologytimes.com/view/top-10-articles-of-the-year-2025
https://medshadow.org/drug-updates-recalls/fda-recalls-and-warnings/fda-drug-recalls-and-warnings-atorvastatin-labeling-mix-up-with-muscle-relaxant-cyclobenzaprine-and-more/
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/private-label-skin-care-inc-715880-12182025
